allergic fungal rhinosinusitis epidemiology forecast

Key Highlights

• Allergic fungal rhinosinusitis (AFR) is a noninvasive subtype of chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP).
• AFR has a worldwide distribution pattern with varying prevalence.

DelveInsight’s “Allergic Fungal Rhinosinusitis (AFR) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of AFR, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020–2034

Allergic Fungal Rhinosinusitis (AFR) Understanding and Treatment Algorithm

Allergic Fungal Rhinosinusitis (AFR) Overview

AFR is a common sinus infection caused by fungi present in the environment. These fungi trigger an allergic reaction, leading to thick fungal material, sticky mucus, and blocked sinuses. People with AFR often have allergies, nasal polyps, and sometimes asthma. The condition usually leads to long-term sinus inflammation, which can affect the sense of smell. If not treated, it can cause the eyeball to shift and even result in vision loss.

Allergic Fungal Rhinosinusitis (AFR) Diagnosis

Diagnosis of AFR involves a combination of clinical history, imaging, histopathology, and immunologic findings. Patients typically present with persistent sinus symptoms unresponsive to standard treatments, often with nasal polyps, atopy, and unilateral sinus involvement. The Bent and Kuhn criteria are widely accepted, requiring evidence of type I hypersensitivity, nasal polyposis, characteristic CT findings, eosinophilic mucin without tissue invasion, and positive fungal staining. Imaging reveals sinus expansion with bone remodeling, especially in the ethmoid sinus, while MRI shows distinctive signal patterns due to the high protein content of allergic mucin. Histologically, allergic mucin contains eosinophils and Charcot-Leyden crystals, with fungal elements visible on special stains. Elevated total IgE and broad allergic sensitization further support the diagnosis.

Further details related to country-based variations in diagnosis are provided in the report

Allergic Fungal Rhinosinusitis (AFR) Epidemiology

The AFR epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total prevalent cases of Allergic Fungal Rhinosinusitis (AFR), total diagnosed prevalent cases of Allergic Fungal Rhinosinusitis (AFR), age-specific diagnosed prevalent cases of Allergic Fungal Rhinosinusitis (AFR), and gender-specific diagnosed prevalent cases of Allergic Fungal Rhinosinusitis (AFR) in the 7MM, covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.

• AFR affects approximately 5% to 10% of patients with a history of chronic rhinosinusitis.
• The prevalence of AFR ranges from 1% to 20% in patients with chronic rhinosinusitis and can be as high as 27% in patients with chronic rhinosinusitis with nasal polyps.
• AFRS is more common in atopic adolescents and young adults, 20 to 30 years old, who are immunocompetent and reside in temperate, humid climates.
• Up to 24% of patients with AFR also have asthma, which, although significant, is a weaker association than in other forms of CRSwNP in which asthma can coexist in up to 50% of patients.
• Recent data suggest that chronic rhinosinusitis affects approximately 10.9% of the European adult population, with an incidence of 1100 cases per 100,000 patients per year. The estimated burden was 1,141,000 cases of fungal rhinosinusitis in Italy.
• Allergic fungal rhinosinusitis is less prevalent in Japan than in Western nations.
• Among the diagnosed prevalent cases of AFR, nearly 53% of them were female and 46% were male.

Allergic Fungal Rhinosinusitis (AFR) Report Insights

• Allergic Fungal Rhinosinusitis (AFR) Report Insights
• Patient population
• Country-wise epidemiology distribution

Allergic Fungal Rhinosinusitis (AFR) Report Key Strengths

• Ten-year forecast
• 7MM coverage
• AFR epidemiology segmentation

FAQs

• What are the disease risks, burdens, and unmet needs of food allergy? What will be the growth opportunities across the 7MM concerning the patient population with AFR?
• What is the historical and forecasted AFR patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives on the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.